• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $GLS

    Gelesis Holdings Inc.

    Subscribe to $GLS
    $GLS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

    IPO Year: 2020

    Exchange: NYSE

    Website: https://www.gelesis.com

    Recent Analyst Ratings for Gelesis Holdings Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Gelesis Holdings Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Puretech Health Plc

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      9/21/23 4:30:07 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Puretech Health Plc

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      6/14/23 4:30:15 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Puretech Health Plc

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      5/31/23 5:30:09 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Puretech Health Plc

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      5/3/23 4:30:31 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Kucherlapati Raju S bought $44,520 worth of shares (100,000 units at $0.45), increasing direct ownership by 111% to 190,264 units

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      11/22/22 6:20:30 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Kucherlapati Raju S bought $47,947 worth of shares (24,625 units at $1.95), increasing direct ownership by 38% to 90,264 units

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      6/17/22 10:46:03 AM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Sannino Alessandro

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      6/13/22 4:41:16 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Chiquette Elaine was granted 80,500 shares, increasing direct ownership by 44% to 263,079 units

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      6/10/22 12:12:50 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Wildman Jane was granted 50,182 shares

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      5/9/22 4:19:18 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Perks Dominic was granted 49,270 shares

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      5/9/22 4:18:38 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Gelesis Holdings Inc. SEC Filings

    See more
    • Gelesis Holdings Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update, Financial Statements and Exhibits

      8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)

      10/30/23 8:58:39 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form CT ORDER filed by Gelesis Holdings Inc.

      CT ORDER - GELESIS HOLDINGS, INC. (0001805087) (Filer)

      10/19/23 2:14:03 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gelesis Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)

      10/16/23 4:15:09 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13E3/A filed by Gelesis Holdings Inc. (Amendment)

      SC 13E3/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

      9/29/23 5:12:08 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRER14A filed by Gelesis Holdings Inc.

      PRER14A - GELESIS HOLDINGS, INC. (0001805087) (Filer)

      9/29/23 4:41:12 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gelesis Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)

      9/20/23 5:14:16 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13E3/A filed by Gelesis Holdings Inc. (Amendment)

      SC 13E3/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

      9/7/23 4:41:01 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRER14A filed by Gelesis Holdings Inc.

      PRER14A - GELESIS HOLDINGS, INC. (0001805087) (Filer)

      9/7/23 4:03:09 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gelesis Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)

      9/6/23 5:09:02 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gelesis Holdings Inc. filed SEC Form 8-K: Leadership Update

      8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)

      8/21/23 4:02:39 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care